- Home
- CLRB vs CODX Comparison
CLRB vs CODX Comparison
Compare CLRB & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- CODX
- Stock Information
- Founded
- CLRB 2002
- CODX 2013
- Country
- CLRB United States
- CODX United States
- Employees
- CLRB N/A
- CODX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- CLRB Health Care
- CODX Health Care
- Exchange
- CLRB Nasdaq
- CODX Nasdaq
- Market Cap
- CLRB 17.5M
- CODX 16.9M
- IPO Year
- CLRB N/A
- CODX 2017
- Fundamental
- Price
- CLRB $4.97
- CODX $0.37
- Analyst Decision
- CLRB Hold
- CODX Buy
- Analyst Count
- CLRB 2
- CODX 2
- Target Price
- CLRB N/A
- CODX $2.00
- AVG Volume (30 Days)
- CLRB 110.6K
- CODX 2.6M
- Earning Date
- CLRB 11-17-2025
- CODX 11-06-2025
- Dividend Yield
- CLRB N/A
- CODX N/A
- EPS Growth
- CLRB N/A
- CODX N/A
- EPS
- CLRB N/A
- CODX N/A
- Revenue
- CLRB N/A
- CODX $1,003,653.00
- Revenue This Year
- CLRB N/A
- CODX N/A
- Revenue Next Year
- CLRB N/A
- CODX $31.58
- P/E Ratio
- CLRB N/A
- CODX N/A
- Revenue Growth
- CLRB N/A
- CODX N/A
- 52 Week Low
- CLRB $4.11
- CODX $0.23
- 52 Week High
- CLRB $66.00
- CODX $1.35
- Technical
- Relative Strength Index (RSI)
- CLRB 45.44
- CODX 50.63
- Support Level
- CLRB $4.56
- CODX $0.37
- Resistance Level
- CLRB $4.98
- CODX $0.44
- Average True Range (ATR)
- CLRB 0.35
- CODX 0.04
- MACD
- CLRB -0.13
- CODX -0.00
- Stochastic Oscillator
- CLRB 18.11
- CODX 45.53
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.